DAXOR CORPORATION - CLOSED END FUND

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

25 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024

22 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

18 Mar 2024 13:18:00 By Nasdaq GlobeNewswire

Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

18 Mar 2024 13:18:00 By Nasdaq GlobeNewswire

Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients

08 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference

26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions

12 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts

07 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting

29 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress

16 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES

09 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

02 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients

13 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume

09 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Expert Panelists Advocate Use of Daxor’s Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting

13 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting

11 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program

04 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023

27 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL’23 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)

26 Sep 2023 07:00:01 By Nasdaq GlobeNewswire